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Abstract
Background: We recently reported that self- evaluation of the incidence and severity 
of treatment- related side effects (TSEs) using a National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) v4.0- based question-
naire was feasible and more informative than doctor reports in patients undergoing 
standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- 
and doctor- evaluated day of onset and duration of TSEs in the same population.
Patients and methods: Six hundred and four patients were enrolled at 11 sites in 
Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, 
anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated 
into Italian and rephrased. Questionnaires were administered after the first and third 
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1 |  INTRODUCTION
The collection and analysis of treatment- related side effects 
(TSEs) are critical to the management of patients with cancer 
both in clinical trials and in daily practice.1,2 Systems like 
the National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE) are integral to clini-
cal trials where measures of treatment- related toxicity are 
critical for establishing the risk- benefit ratio of new treat-
ments. Interestingly, a number of papers have reported mod-
erate to substantial underestimation of TSE reporting when 
investigator- collected data are compared to corresponding 
data provided by patients using adapted questionnaires.3-8 
For this reason, the NCI has promoted the development of a 
“patient” version of the CTCAE (patient- reported outcome 
(PRO)- CTCAE), which is currently being translated and val-
idated in different languages and integrated, together with 
more established PROs, in clinical trials.9-13
If patient- and doctor- reported TSEs are discrepant in the 
prospective clinical trial context, it is likely that TSE under-
estimates are even greater in patients receiving standard treat-
ments in clinical practice, as there is no standardized system 
to collect them. TSE underreporting may have consequences 
for quality of life and disease- related outcomes.8,14,15
Therefore, we developed a CTCAE v4.0- based ten- item 
patient questionnaire by translating grade of toxicity defi-
nitions into Italian and administering it to a large cohort of 
patients with breast cancer receiving adjuvant chemotherapy 
at different Italian institutions.16 We showed that doctors 
underestimate TSE incidence and severity in clinical prac-
tice, with a more pronounced effect in high- volume centers. 
However, our questionnaire also reported the day of onset and 
duration for each TSE considered, allowing us to here to ana-
lyze and compare these two patient- and doctor- reported TSE 
dimensions.
2 |  PATIENTS AND METHODS
The details of our prospective trial evaluating a CTCAE 
v4.0- based patient questionnaire are reported elsewhere.16 
Our ten- item paper questionnaire included nausea, vomit-
ing, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain 
(generic), paresthesia, and dyspnea. For each item, defini-
tions and severity grades were translated into Italian from the 
CTCAE version 4.0. In addition to severity grade, the ques-
tionnaire contained fields to record the day of onset for each 
item (where the day of chemotherapy administration was 
day one), the duration in days, and persistence at the time of 
questionnaire administration (Figure S1). When the Italian 
translation of CTCAE version 4.0 became available and was 
endorsed by the Italian Association of Medical Oncology in 
mid- 2011, the questionnaire was rechecked and there were 
no translational discrepancies.17
Patients were instructed to complete the questionnaire at 
the end of the first cycle (usually on day one of the second 
cycle of planned chemotherapy) and at the end of the third 
cycle (usually on day one of the fourth cycle of planned che-
motherapy). Dedicated nurses provided instructions on how 
to complete the questionnaires at the time of obtaining in-
formed consent, with no further assistance given during the 
study. Patients were also provided with a diary to help record 
chemotherapy cycles. At each time- point, information on TSEs was extracted from 
the medical charts and compared to patient questionnaires.
Results: A total of 594 and 573 paired patient and doctor questionnaires were col-
lected after cycles one and three, respectively. TSE duration was significantly longer 
when reported by patients compared to doctors for six and seven of ten items after 
cycles one and three, respectively. Due to the combined effect of doctor underreport-
ing of TSE incidence and duration, the mean percentages of cycle days with TSEs 
were significantly higher for all ten items when based on patient reports. Day of onset 
could not be evaluated because of insufficient numbers of complete records.
Conclusions: Self- reporting TSE duration is feasible using a CTCAE- derived ques-
tionnaire. As doctors tend to underestimate TSE incidence and duration, patient- 
reported outcomes should be incorporated into clinical practice, perhaps using 
eHealth technologies, to harness their potential to better estimate total TSE burden.
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onset and duration of specific adverse events, but this was 
not part of the formal study materials. At each participating 
Institution, dedicated nurses extracted side effect information 
from the medical records of patients and filled in “doctor” 
questionnaires at matching time- points. These questionnaires 
were collected exclusively by nurses and were not available 
to the treating doctors.
2.1 | Statistical analysis
Medians and means are reported together with their ranges 
and standard errors, respectively. Paired medians and means 
were compared by the Wilcoxon signed- rank test and by 
Student’s t test for paired data. Proportions in unrelated sam-
ples were compared by the chi- squared test. Statistical sig-
nificance was set at P < 0.05 (two- tailed).
3 |  RESULTS
Of 604 patients with early breast cancer enrolled in the study 
at 11 Italian Institutions, three withdrew informed consent 
before the first cycle of chemotherapy. Patient demograph-
ics are summarized in Table 1. Overall, 596 and 581 patient 
questionnaires were collected after cycles one and three of 
adjuvant chemotherapy, respectively. Of these, 594 and 573 
had a corresponding (doctor) questionnaire extracted from 
the medical charts at the same time- points, respectively. In 
patients reporting TSEs, the average proportions of question-
naires with complete information on day of onset and du-
ration were 70% and 95%, respectively (first questionnaire), 
and 75% and 95%, respectively (second questionnaire, Tables 
S1 and S2). Corresponding figures for doctor reports were 
29% and 95%, respectively (first questionnaire), and 31% and 
97%, respectively (second questionnaire, Tables S1 and S2).
The median day of onset and median durations as reported 
by patients and described by doctors in the first and second 
questionnaires are summarized in Tables S3 and S4. As data 
on day of onset were missing in a high proportion of doc-
tor questionnaires, patient and doctor reports of day of onset 
could not be formally compared.
The median duration values of each of the ten adverse 
events as reported by patients and as described by doctors 
after cycles one and three were only compared for pairs of 
charts where both patients and doctors reported each item as 
present (any grade). After cycle one, with the exception of 
vomiting, pain, neuropathy, and dyspnea, the median dura-
tion of symptoms was longer when reported by patients than 
doctors, with notable differences for nausea (4 vs 2 days; 
P < 0.01), constipation (3 vs 1 days; P < 0.01), anorexia (3 
vs 1 days; P < 0.01), diarrhea (3.5 vs 1 day; P = 0.02), and 
fatigue (4 vs 1 days; P < 0.01) (Table 2). Results were similar 
after the third cycle, with the difference that vomiting also 
lasted longer when reported by patients than doctors and that 
the difference in the duration of diarrhea was not statistically 
significant (Table 3).
To analyze the combined effect of differences in reporting 
incidence and duration, the mean percentages of cycle days 
with a certain side effect were calculated for each TSE (total 
days with the side- effect/total days from the date of chemo-
therapy administration and that of data collection*100) as 
reported by patients and doctors. Here, “0” days described 
a TSE that either did not occur or that was missed by the 
patient or the doctor. Results for the first questionnaire are 
displayed in Figure 1 and in Table S5; the mean percentage of 
cycle days with each TSE was significantly higher when re-
ported by patients compared to doctors. Similar results were 
obtained with the second questionnaire (data not shown).
4 |  DISCUSSION
Here, we exploited our CTCAE V4.0- based questionnaire 
study to integrate data on time of onset and duration of ten 
common TSEs experienced by breast cancer patients treated 
with adjuvant chemotherapy in clinical practice.
Table 1. Patients demographics
Variable Number % or ranges
Median age in years 53.4 45.0- 62.7
Histology, N (%)
Ductal 490 82
Lobular 54 9
Other 53 8
Missing 4 <1
Type of breast surgery
Mastectomy 242 40
Breast- conserving 
surgery
354 49
Missing 5 1
Type of axillary surgery
Sentinel lymph node 
biopsy
268 45
Axillary dissection 328 55
Missing 5 1
Type of adjuvant chemotherapy
FEC90 or FEC100 387 64
AC o EC 133 22
TC 81 14
FEC90, 5- fluorouracil (600 mg/m2), epi- doxorubicin (90 mg/m2), cyclophospha-
mide (600 mg/m2); FEC100, 5- fluorouracil (500 mg/m2), epi- doxorubicin 
(100 mg/m2), cyclophosphamide (500 mg/m2); AC, doxorubicin (60 mg/m2), cy-
clophosphamide (600 mg/m2); EC, epi- doxorubicin (90 mg/m2), cyclophospha-
mide (600 mg/m2); TC, docetaxel (75 mg/m2), cyclophosphamide (600 mg/m2).
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In our prior publication comparing patient- and doctor- 
reported TSE incidence and severity, we described a high rate 
of questionnaire completion, except for the field indicating 
persistence of the TSEs at the time of the visit.16 When re-
viewing the dataset, despite a high completion rate, a sub-
stantial number of “day of onset” entries in both the patient 
and doctor questionnaires were “0” values. As the day of 
onset had to be counted from the day of the last chemotherapy 
administration (day one), we considered all the 0 values as 
incorrect and treated them as missing values. Consequently, 
for this toxicity dimension, we were unable to perform a for-
mal statistical comparison of paired patient and doctor ques-
tionnaires for all the items because due to insufficient paired 
data. The descriptive analysis reported in Tables S3 and S4 
suggested no major differences in the median day of onset 
but a larger variability in patient- reported nausea, vomiting, 
constipation, anorexia, and dysgeusia.
Conversely, data on TSE duration were of better quality 
and reported in over 90% of patient and doctor questionnaires. 
In paired comparisons, patients reported longer duration after 
the first and third cycles for six and seven of the ten items, 
respectively. By combining information on incidence and du-
ration, we determined that the mean percentage of cycle days 
with a certain toxicity was significantly higher in patient than 
doctor reports. These results indicate major discrepancies in 
the subjective experience of patients given the opportunity to 
self- collect TSE to medical chart reports during routine visits 
at oncology centers compared to doctor reports.
Nevertheless, our data suggest that longitudinal TSE 
evaluations by patient self- administered questionnaires are 
Table 2. Summary of pairwise comparisons of median duration of TSEs after cycle one (first questionnaire)
Item
N paired questionnaires  
reporting the itema
Duration patient  
median (range)
Duration doctor  
median (range) P
Nausea 175 4 (1- 21) 2 (1- 21) <0.01
Vomiting 54 2 (1- 6) 1 (1- 10) N.S.
Constipation 52 3 (1- 20) 1 (1- 14) <0.01
Anorexia 34 3 (1- 15) 1 (1- 10) <0.01
Dysgeusia 38 2 (1- 21) 1 (1- 20) <0.01
Diarrhea 17 3.5 (1- 13) 1 (1- 7) 0.02
Fatigue 112 4 (1- 21) 1 (1- 14) <0.01
Pain 28 1 (1- 15) 1 (1- 15) NS
Paresthesia 13 1 (1- 6) 1 (1- 6) NS
Dyspnea 11 1 (1- 6) 1 (1- 6) NS
Number in parentheses indicate paired patient and doctor questionnaires available for the analysis of incidence.
NS, nonsignificant.
aNumbers indicate the pairs of questionnaires where both the patient and the doctor indicated the occurrence of the side effect and for which information on duration was 
present.
Table 3. Summary of pairwise comparisons of median duration after cycle three (second questionnaire)
Item
N paired questionnaires  
reporting the item  
(grade ≥1)a
Duration patient  
median (range)
Duration doctor  
median (range) P
Nausea 177 4 (1- 18) 2 (1- 21) <0.01
Vomiting 53 2 (1- 8) 1 (1- 5) <0.01
Constipation 54 3 (1- 20) 1 (1- 18) <0.01
Anorexia 35 4 (1- 15) 1 (1- 15) 0.01
Dysgeusia 48 2 (1- 21) 1 (1- 21) 0.03
Diarrhea 12 3 (1- 12) 1 (1- 7) 0.06
Fatigue 103 4 (1- 40) 1 (1- 21) <0.01
Pain 27 2 (1- 21) 1 (1- 21) NS
Paresthesia 16 1 (1- 10) 1 (1- 10) NS
Dyspnea 22 1 (1- 19) 1 (1- 18) NS
aNumbers indicate the pairs of questionnaires where both the patient and the doctor indicated the occurrence of the side effect and for which information on duration was 
present.
   | 5GALIZIA et AL.
feasible and could improve the management of patients un-
dergoing adjuvant chemotherapy for breast cancer.18,19
The metrics and tools available to longitudinally evalu-
ate side effects to dissect and exploit the different TSE di-
mensions in clinical trials evaluating newer treatments have 
recently been reviewed and discussed.20,21 This issue is be-
coming particularly relevant to new treatment paradigms 
such as the chronic administration of low- dose chemother-
apy or use of biologicals. Longitudinal assessment requires 
several TSE dimensions to be collected during treatment 
to feed databases that can generate appropriate metrics. In 
this respect, a tool like our questionnaire or the more stan-
dardized PRO- CTCAE with integrated day of onset and du-
ration could provide such data. Although emphasis is often 
given to acute toxicities from cytotoxic chemotherapy, lon-
gitudinal assessment of the dimensions of timing of onset 
and duration may improve TSE management in routine 
clinical practice. Questionnaires like or own could also be 
converted into Web- based tools or smartphone “eHealth” 
applications for the patient to complete at home, with re-
mote access by medical staff. Some nonrandomized stud-
ies of electronic TSE data capture have been conducted, 
highlighting the promising potential of this approach.22-24 
Importantly, a recently published randomized trial showed 
that advanced cancer patients undergoing treatment man-
aged with a system integrating a Web- based version of the 
PRO- CTCAE and remote control with appropriate actions 
when needed (ie, patients reporting significant worsening 
of a certain TSE) had, compared with usual care, improved 
overall survival.15
In conclusion, here we confirm that patients with breast 
cancer undergoing adjuvant chemotherapy can self- assess 
and report the day of TSE onset and describe their duration. 
The duration of most TSEs was longer when reported by pa-
tients rather than doctors, and the combined effect of longer 
duration and underreporting was an increase in the percent-
age of cycle days with all TSEs. We are now implementing 
an electronic version of our questionnaire in the routine man-
agement of patients with breast cancer undergoing adjuvant 
chemotherapy at our institution.
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